THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, October 22, 2020
The FDA publishes a drug safety communication regarding pregnancy warning for NSAIDs.
SAINT LOUIS PARK, MINNESOTA: The Food and Drug Administration (FDA) has recently published a Drug Safety Communication about nonsteroidal anti-inflammatory drugs (NSAIDs). This communication alerts: NSAIDs used in the second half (20 weeks or later) of pregnancy might cause “rare but serious” kidney problems in the unborn baby. The FDA analyzes this well-known problem and says: “After around 20 weeks of pregnancy, the unborn babies’ kidneys produce most of the amniotic fluid, so kidney problems can lead to low levels of this fluid. Amniotic fluid provides a protective cushion and helps the unborn babies’ lungs, digestive system, and muscles develop.” NSAIDs like ibuprofen, naproxen, diclofenac, and celecoxib are usually used to treat pain and fever.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The FDA needs labeling changes to prescription NSAID labels and over-the-counter (OTC) NSAID Drug Facts Panel labels. These labels should now state that NSAID use should be limited between 20-30 weeks of pregnancy because of the risk of fetal kidney problems and low amniotic fluid that might need to be monitored by the ultrasound. This change is also past warnings to avoid NSAID usage after 30 weeks due to potential fetal heart problems. Also, this warning does not apply to a low dose (81mg) aspirin that is used as directed by a healthcare professional. Frestedt Incorporated are experts in drug labeling updates, including the pregnancy section of the prescription drug labels under the Pregnancy and Lactation Labeling Rule (PLLR). If a company manufactures NSAID drug products, Frestedt Inc. will be pleased to help them navigate and comply with these new label needs.
Frestedt Incorporated is a consulting service organization founded on February 26, 2008, to provide exquisitely targeted clinical, regulatory, and quality system solutions for the pharmaceutical, medical, biotechnology, and food-related industries. The company offers its clients expertise in all product development stages from the bench, preclinical, and clinical trial services to the post-market research and the integration of new safety, efficacy, and performance data into the developing risk management portfolio.
The company was featured in ‘Pharma Tech Outlook’ as the ‘Top 10 CROs-2019.’
More in News